Consensus BioCryst Pharmaceuticals, Inc.

Stocks

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq 08:00:00 10/11/26 am AEDT			5-day change	1st Jan Change
7.630 ^USD	-0.78%		-7.46%	-2.18%

05/11	BioCryst Pharmaceuticals, Inc., Q3 2026 Earnings Call, Nov 04, 2026
05/11	Wedbush Adjusts BioCryst Pharmaceuticals PT to $17 From $18, Maintains Outperform Rating	MT

Evolution of the Average Target: BioCryst Pharmaceuticals, Inc.

Evolution of the Target Price: BioCryst Pharmaceuticals, Inc.

Changes in Analyst Recommendations: BioCryst Pharmaceuticals, Inc.

9352.o0zfhlXqDK1sk6AxYfO4-Aq_k90xAormAJTWY0Smae0.2Q2P5TmYevk18eJFWZrvmUaMyotyQ86TZOCGVjDLLafMfLPUFJp_1wTWmA~6bfa17cf50eb64a553379c2d6eeff50d

Analysts' recommendations: BioCryst Pharmaceuticals, Inc.

05/11	Wedbush Adjusts BioCryst Pharmaceuticals PT to $17 From $18, Maintains Outperform Rating	MT
19/10	Wedbush Cuts Price Target on BioCryst Pharmaceuticals to $18 From $20, Keeps Outperform Rating	MT
10/09	RBC Downgrades BioCryst Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $11 From $13	MT
06/08	RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating	MT
06/08	Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating	MT
07/07	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating	MT
07/04	RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating	MT
26/03	BioCryst Shares Remain Undervalued, RBC Says	MT
28/02	Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating	MT
31/01	RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating	MT
08/01	RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating	MT
30/12	BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says	MT
15/10/25	RBC Raises Price Target on BioCryst Pharmaceuticals to $15 From $14, Keeps Outperform Rating	MT
08/10/25	RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating	MT
01/10/25	Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12	MT
30/06/25	Wedbush Raises Price Target on BioCryst Pharmaceuticals to $18 From $16, Maintains Outperform Rating	MT
06/05/25	RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating	MT
25/02/25	RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating	MT
08/05/24	JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	MT
18/09/23	BioCryst Pharmaceuticals Receives Upgrade From RBC to Outperform From Sector Perform, Price Target Raised to $10 From $9	MT
05/08/23	Jefferies Upgrades BioCryst Pharmaceuticals to Buy From Hold, Price Target is $11	MT
04/08/23	RBC Raises Price Target on BioCryst Pharmaceuticals to $9 From $8, Keeps Sector Perform, Speculative Risk	MT
13/07/23	BofA Securities Upgrades BioCryst Pharmaceuticals to Buy From Neutral, Price Target is $10	MT
07/07/23	RBC Trims BioCryst Pharmaceuticals' Price Target to $8 From $9, Keeps Sector Perform Speculative Risk Rating	MT
21/04/23	Evercore ISI Lowers Price Target on BioCryst Pharmaceuticals to $10 From $13, Maintains Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOCRYST PHARMACEUTICALS, INC.					+168.08%
	WUXI APPTEC CO., LTD.					+34.63%
	ARGENX SE					+17.07%
	LONZA GROUP AG					+8.61%
	BEONE MEDICINES AG					+10.07%
	IQVIA HOLDINGS INC.					+11.85%
	REVOLUTION MEDICINES, INC.					+37.32%
	CELLTRION, INC.					+31.13%
	GENMAB A/S					+10.81%
	INSMED INCORPORATED					+67.25%
	Average					+39.68%
	Weighted average by Cap.					+23.96%